Neoadjuvant and adjuvant therapy of intrahepatic cholangiocarcinoma / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
;
(12): 552-556, 2023.
Article
Dans Chinois
| WPRIM
| ID: wpr-993372
ABSTRACT
Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the secondary bile ducts and their branches within the liver, with high malignancy and poor prognosis. Radical surgical resection is currently the only possible way to cure ICC, but only some patients meet the surgical standards, and even with surgical resection, about 60% of patients will relapse within 1~2 years. Neoadjuvant therapy and adjuvant therapy are important perioperative treatment methods for ICC, with the aim of reducing postoperative recurrence and improving postoperative survival. This article aims to elaborate on the current status and research progress of neoadjuvant therapy and adjuvant therapy for ICC.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Hepatobiliary Surgery
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS